Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors
Didanosine (Videx, ddI)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
Excerpt from Table 10
|Formulation||Dosing Recommendationsa||Use in Pregnancy|
Buffered Tablets (Non-EC):
Videx EC (EC Beadlets) Capsules:
Generic Delayed-Release Capsules:
|Standard Adult Doses
Body Weight ≥60 kg:
Dosing in Pregnancy:
|ddI is not recommended for pregnant women.
Low-moderate placental transfer to fetus.b
ddI should not be used with d4T. Lactic acidosis, sometimes fatal, has been reported in pregnant women receiving ddI and d4T together.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:
Key to Acronyms: ARV = antiretroviral; d4T = stavudine; ddI = didanosine; EC = enteric coated; FDC = fixed-dose combination; PK = pharmacokinetic; TDF = tenofovir disoproxil fumarate
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive